menu
    • menu
    [{"orgOrder":0,"company":"Yaral Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Yaral Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Yaral Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yaral Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Yaral Pharma","sponsor":"Eversana","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Diclofenac Epolamine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Yaral Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Yaral Pharma \/ Yaral Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Yaral Pharma \/ Yaral Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Yaral Pharma

    Menu

    Yaral Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Yaral Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Yaral Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Eversana

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Yaral Pharma Partners With EVERSANA to Support the Commercialization of Its Expanding Generics Portfolio

                            Details : Under the partnership, EVERSANA will support the expansion of its portfolio of pain and endocrinology products in the U.S., including Flector (diclofenac epolamine), a topical prescription therapy for acute pain due to minor strains, sprains, and contusi...

                            Brand Name : Flector

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 22, 2023

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Eversana

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Yaral Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Yaral Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%

                            Details : Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

                            Brand Name : Diclofenac Epolamine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 03, 2023

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth